Chang Shan 2000 Year Old Chinese Herbal Medicine Working Process Uncovered

Working of Chang Shan medicine uncovered

10:58 AM, 27th December 2012
2000 Year Old Chinese Herbal Medicine Chang Shan
Scripps Research Institute scientists have determined a molecular structure that helps explain how the Chinese herbal medicine Chang Shan works.

LA JOLLA, US: The mysterious inner workings of Chang Shan, a Chinese herbal medicine used for thousands of years to treat fevers associated with malaria, have been uncovered thanks to a high-resolution structure solved at The Scripps Research Institute (TSRI). Described in the journal Nature this week, the structure shows in atomic detail how a two-headed compound derived from the active ingredient in Chang Shan works.

Scientists have known that this compound, called halofuginone, can suppress parts of the immune system, but nobody knew exactly how. The new structure shows that, like a wrench in the works, halofuginone jams the gears of a molecular machine that carries out ‘aminoacylation,’ a crucial biological process that allows organisms to synthesize the proteins they need to live.

“Our new results solved a mystery that has puzzled people about the mechanism of action of a medicine that has been used to treat fever from a malaria infection going back probably 2,000 years or more,” said Paul Schimmel, Professor, TSRI. Schimmel led the research with TSRI postdoctoral fellow Huihao Zhou, PhD.

Halofuginone has been in clinical trials for cancer, but the high-resolution picture of the molecule suggests it has a modularity that would make it useful as a template to create new drugs for numerous other diseases.

Aminoacylation is a crucial step in the synthesis of proteins, the end products of gene expression. When genes are expressed, their DNA sequence is first read and transcribed into RNA, a similar molecule. Necessary for this translation process are a set of molecules known as transfer RNAs (tRNAs), which shuttle amino acids to the growing protein chain where they are added like pearls on a string. But before the tRNAs can move the pearls in place, they must first grab hold of them.

Aminoacylation is the biological process whereby the amino acid’s pearls are attached to these tRNA shuttles. A class of enzymes known as aminoacyl-tRNA synthetases is responsible for attaching the amino acids to the tRNAs, and Schimmel and his colleagues have been examining the molecular details of this process for years. Their work has given scientists insight into everything from early evolution to possible targets for future drug development.

Over time what has emerged as the picture of this process basically involves three molecular players: a tRNA, an amino acid and the aminoacyl-tRNA synthetase enzyme that brings them together. A fourth molecule called ATP is a microscopic form of fuel that gets consumed in the process.

The new work shows that halofuginone gets its potency by interfering with the tRNA synthetase enzyme that attaches the amino acid proline to the appropriate tRNA. It does this by blocking the active site of the enzyme where both the tRNA and the amino acid come together, with each half of the halofuginone blocking one side or the other.

Interestingly, said Schimmel, ATP is also needed for the halofuginone to bind. Nothing like that has ever been seen in biochemistry before.

© The Scripps Research Institute News




Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Mitsui, Formosa form electrolyte solution JV in China

TOKYO, JAPAN/TAIPEI, TAIWAN: Mitsui Chemicals and Formosa Plastics Corporation have entered into an agreement on 27 December 2012 to form a joint vent ...

Read more
Clariant to sell textile, paper and emulsions businesses to SK Capital

MUTTENZ, SWITZERLAND: Clariant has signed an agreement to divest its textile chemicals, paper specialties and emulsions businesses to SK Capital. The ...

Read more
Mitsubishi to acquire Qualicaps from Carlyle Group

  TOKYO, JAPAN: The Carlyle Group has agreed to sell its entire shareholdings in Qualicaps to Mitsubishi Chemical Holdings. Further details of t ...

Read more
Statoil acquires Vale’s 25 pc stake in Espirito Santo Basin offshore Brazil

STAVANGER, NORWAY: Statoil is expanding its exploration portfolio through the acquisition of 25 per cent participating interest from Vale SA in BM-ES- ...

Read more
Indian cabinet approves stake sale in Rashtriya Chemicals

DELHI, INDIA: The Indian cabinet approved selling a further stake in state-run Rashtriya Chemicals & Fertilizers Ltd. The move is part of the gove ...

Read more
KBR, AYTB to provide refinery maintenance services in Saudi Arabia

HOUSTON, US: KBR and AYTB have signed a seven-year contract to provide refinery maintenance services for the Saudi Aramco Total Refining and Petrochem ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X